With Nelson Stone out of contention due to injury, it is now a two horse race between sprinter Theo Piniau and veteran 400m hurdler Mowen Boino.The deadline is June 19 and that is when Athletics PNG will nominate to the PNG Olympic Committee the athlete who has the best performance.This will be determined by reference to the IAAF scoring tables, which are an internationally recognised method of comparing performance in different events.Boino currently leads the race with his time of 52.03 seconds in the 400m hurdles which are worth 1031 points on the tables. Piniau’s best performance is 21.39 seconds for the 200m and that is worth 1018 points.With the US College season now over and with no more relay duties, the youngster from East New Britain can fully focus on his dream of making it to his first Olympic Games, whereas Boino is aiming to make up for the disappointment of missing out on his fourth Games in 2012.The pair will meet up on Thursday morning US time in the Sunshine State of Florida for a series of meets in the Miami/Fort Lauderdale area, starting with the first of the Sunshine Invitational Sprint Series meets this Saturday at the University of Miami Cobb Stadium.This will be followed by the Star Athletics Sprint Series at Montverde on June 11, which is expected to be huge, and possibly a race at Jacksonville on June 12.The final meet will be at Cardinal Newman on June 18. With athletes from the USA, Canada and the Caribbean looking for Olympic qualifiers, these meets are expected to be very competitive.Philadelphia based coach Dior Lowry, who has worked with a number of US-based PNG athletes in the past couple of years and accompanied the PNG team to the IAAF World Relay Championships last year, will manage the two athletes in Florida and provide any coaching assistance they require.
Source:http://casemed.case.edu/cwrumed360/news-releases/release.cfm?news_id=1271&news_category=8 Jun 6 2018It takes an “A” team to make headway against glioblastoma, a highly aggressive type of brain cancer. Glioblastoma is the most common type of malignant brain tumor in adults. In addition to the caliber of the researchers involved, in this case “A” also stands for atlas.A key member of the team, Jill S. Barnholtz-Sloan, PhD, Sally S. Morley Designated Professor in Brain Tumor Research at Case Western Reserve University School of Medicine, and approximately 80 other internationally renowned neurologists, bioinformaticians, and pathologists from the United States and India recently published details of the Ivy Glioblastoma Atlas in ScienceThe atlas maps out comprehensive, visually-rich information on the anatomic and genetic bases of glioblastoma at the cellular and molecular levels associated with the disease. It is aimed at helping researchers and physicians improve the diagnosis and treatment of glioblastoma, including finding new drug targets. While Atlas-based data have been previously available, the new paper in Science represents the first published research outlining the project in detail.According to Barnholtz-Sloan, there are three aims to the venture. The first is to make all the relevant data fully transparent and available. The second is to create a road map of all of the different cells and potential molecular changes that occur in these cells in a glioblastoma. And the third, is to build a better understanding of how much heterogeneity can be found in these tumors.”Currently we provide the same standard treatment of surgery, followed by radiation plus chemotherapy, for all glioblastoma patients,” says Barnholtz-Sloan, who is also professor and associate director for bioinformatics/translational informatics at CWRU’s School of Medicine. “But the tumors are not all the same. They have different molecular changes, which means that we may need to provide separate, tailored treatments to tackle each one. By identifying unique features of these tumors that may benefit from targeted therapies, the Atlas will enable patients to experience the benefits of precision medicine, increasing the chances for better response to treatment and hence better survival.”Related StoriesStudy offers clues about how to prevent brain inflammation in Alzheimer’sNew therapy shows promise in preventing brain damage after traumatic brain injuryHow cell-free DNA can be targeted to prevent spread of tumorsIn virtually all cases of glioblastoma, excised tumors are assessed by highly specialized pathologists, who confirm the presence of malignancy and provide details about the unique characteristics of the tumors they examine. For this project, Barnholtz-Sloan assisted the team in developing a study design to assess the concordance between features outlined in the tumors by both these human experts and automated machine-learning techniques. “In many ways it’s a belt and suspenders approach,” she says. “The gold standard is the pathologist. Machine-driven analysis adds value by bringing further information to the findings of the pathologists. In the article we published, we found that the concordance rates were very high; 85-95 percent.”By way of comparison, Barnholtz-Sloan cites the case of medulloblastoma, a common type of malignant brain tumor mostly seen in children. In medulloblastoma, researchers have been able to group tumors into four distinct molecularly-defined groups, which have specific drugs that would work best within each subtype. The new Atlas hopes to replicate this success in glioblastoma.”As more new information is added to the Atlas and the associated database for clinical and genomic data, we believe that it will continue to be very valuable research and treatment tool, allowing more refined diagnosis and treatment and enabling researchers to generate potentially life-extending hypotheses about causes and treatments,” said Barnholtz-Sloan.